You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東誠藥業(002675.SZ):子公司安迪科與ImaginAb簽署合作意向書 進入免疫治療領域
格隆匯 01-10 20:13

格隆匯1月10日丨東誠藥業(002675.SZ)發佈,近日,公司全資子公司南京江原安迪科正電子研究發展有限公司(“安迪科”)與ImaginAb, Inc.(簡稱 “ImaginAb”)簽署了《非約束性合作意向書》,達成了初步合作意向。

安迪科為獨家經銷商,將取得ImaginAb專利權下規定的權利及相關數據,進而在中國開展協議許可產品“zirconium Zr 89 crefmirlimab berdoxam”(簡稱“目標產品”)的開發、註冊、製造和銷售。

ImaginAb是一家開創性的生物技術公司,專注於開發下一代免疫腫瘤學顯像劑和放射性藥物治療(或RPT)。其主要產品“zirconium Zr 89 crefmirlimab berdoxam”是以CD8 T細胞為靶點,標記微型抗體的PET示蹤劑,可實現全身範圍內CD8T細胞的無創成像,目前處於臨牀二期。已與其就免疫治療臨牀試驗中的PET顯像開展合作的包括輝瑞、拜爾、默克、羅氏、阿斯利康等跨國藥企。

目標產品通過成像CD8T細胞可實現病人體內免疫細胞的可視化,以此來監測接受治療的患者體內的免疫反應,從而快速判斷癌症免疫療法的療效。通過引入目標產品,公司進入免疫治療領域,擴寬業務領域。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account